Connect Biopharma Holdings Limited
$2.68
▲
9.93%
2026-04-21 06:08:01
www.connectbiopharm.com
NGM: CNTB
Explore Connect Biopharma Holdings Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$158.82 M
Current Price
$2.68
52W High / Low
$3.82 / $0.65
Stock P/E
—
Book Value
$0.74
Dividend Yield
—
ROCE
-24.19%
ROE
-82.72%
Face Value
—
EPS
$-1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
64
Beta
—
Debt / Equity
1.64
Current Ratio
3.74
Quick Ratio
3.74
Forward P/E
-3.77
Price / Sales
2,490.47
Enterprise Value
$115.74 M
EV / EBITDA
-2.02
EV / Revenue
1,808.41
Rating
Strong Buy
Target Price
$7.9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 2. | Forte Biosciences, Inc. | $34.43 | — | $674.68 M | — | -113.91% | -1.22% | $35.8 / $4.9 | $4.71 |
| 3. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 4. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 5. | Upstream Bio, Inc. | $9.99 | — | $543.66 M | — | -47.12% | -35.44% | $33.68 / $7.25 | $6.26 |
| 6. | Caribou Biosciences, Inc. | $2.29 | — | $212.6 M | — | -90.82% | -78.97% | $3.54 / $0.71 | $1.28 |
| 7. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0.02 M | 0.05 M | 0 M | 0.7 M | — |
| Operating Profit | -15.53 M | -17.68 M | -13.42 M | -11.45 M | -9.62 M | — |
| Net Profit | -15.11 M | -17.2 M | -12.9 M | -10.27 M | -8.91 M | — |
| EPS in Rs | -0.27 | -0.3 | -0.23 | -0.18 | -0.16 | -0.23 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.06 M | 26.03 M | 0 M | 0 M |
| Operating Profit | -58.07 M | -22.45 M | -69.06 M | -116.51 M |
| Net Profit | -55.48 M | -15.63 M | -62.11 M | -118.09 M |
| EPS in Rs | -0.98 | -0.28 | -1.1 | -2.09 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 56.08 M | 101.28 M | 127.38 M | 174.01 M |
| Total Liabilities | 14.1 M | 9.12 M | 25.88 M | 16.52 M |
| Equity | 41.98 M | 92.17 M | 101.5 M | 157.49 M |
| Current Assets | 50.93 M | 96.96 M | 122.55 M | 155.78 M |
| Current Liabilities | 13.61 M | 8.46 M | 25.29 M | 15.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.21 M | -23.61 M | -47.74 M | -101.52 M |
| Investing CF | 9.82 M | -3.45 M | 74.98 M | -86.24 M |
| Financing CF | 1.09 M | 0.23 M | 0.04 M | -0.09 M |
| Free CF | -51.64 M | -24.36 M | -47.82 M | -105.92 M |
| Capex | -0.43 M | -0.75 M | -0.08 M | -4.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 74.84% | 47.41% | — | — |
| Profit Margin % | -60.03% | — | — | — |
| Operating Margin % | -86.24% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -83.71% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.